HK1065703A1 - Prophylactic and therapeutic use of hydroxysteroids - Google Patents
Prophylactic and therapeutic use of hydroxysteroidsInfo
- Publication number
- HK1065703A1 HK1065703A1 HK04108498.6A HK04108498A HK1065703A1 HK 1065703 A1 HK1065703 A1 HK 1065703A1 HK 04108498 A HK04108498 A HK 04108498A HK 1065703 A1 HK1065703 A1 HK 1065703A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hydroxysteroids
- prophylactic
- therapeutic use
- hydroxy
- steroids
- Prior art date
Links
- 230000000069 prophylactic effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000006378 damage Effects 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0119810A GB2378898A (en) | 2001-08-14 | 2001-08-14 | Prophylactic and therapeutic use of hydroxysteroids |
| PCT/GB2002/003770 WO2003015791A1 (en) | 2001-08-14 | 2002-08-13 | Phophylactic and therapeutic use of hydroxysteroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1065703A1 true HK1065703A1 (en) | 2005-03-04 |
Family
ID=9920376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK04108498.6A HK1065703A1 (en) | 2001-08-14 | 2004-10-29 | Prophylactic and therapeutic use of hydroxysteroids |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8148355B2 (xx) |
| EP (1) | EP1416937B1 (xx) |
| JP (1) | JP4541698B2 (xx) |
| KR (1) | KR100895281B1 (xx) |
| CN (1) | CN1700920B (xx) |
| AT (1) | ATE429919T1 (xx) |
| AU (1) | AU2002321472B2 (xx) |
| CA (1) | CA2457050C (xx) |
| CY (1) | CY1109233T1 (xx) |
| DE (1) | DE60232154D1 (xx) |
| DK (1) | DK1416937T3 (xx) |
| ES (1) | ES2324859T3 (xx) |
| GB (1) | GB2378898A (xx) |
| HK (1) | HK1065703A1 (xx) |
| IL (2) | IL160362A0 (xx) |
| NO (1) | NO334819B1 (xx) |
| NZ (1) | NZ531100A (xx) |
| PT (1) | PT1416937E (xx) |
| RU (1) | RU2329049C2 (xx) |
| WO (1) | WO2003015791A1 (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0409498D0 (en) * | 2004-04-28 | 2004-06-02 | Hunter Fleming Ltd | Transdermal steroid formulation |
| US7910755B2 (en) | 2004-09-29 | 2011-03-22 | Harbor Biosciences, Inc. | Stem cell expansion and uses |
| CA2670957A1 (en) | 2006-11-30 | 2008-06-05 | Hunter-Fleming Limited | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| GB0623971D0 (en) * | 2006-11-30 | 2007-01-10 | Hunter Fleming Ltd | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| EP2653163A1 (en) * | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| CN105078954A (zh) * | 2015-08-20 | 2015-11-25 | 南京华宽信息咨询中心 | 一种治疗急性肾衰药物及其应用 |
| CN105168197A (zh) * | 2015-08-22 | 2015-12-23 | 南京华宽信息咨询中心 | 一种治疗肾功能不全药物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686438A (en) * | 1993-03-09 | 1997-11-11 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| JP2858046B2 (ja) * | 1993-03-09 | 1999-02-17 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | 組織損傷を有する個人の組織生活能力の消失の予防乃至は軽減のための製薬組成 |
| US5846963A (en) * | 1995-06-07 | 1998-12-08 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5977095A (en) * | 1993-03-09 | 1999-11-02 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome |
| US5753640A (en) * | 1995-06-07 | 1998-05-19 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| IT1282289B1 (it) | 1995-06-23 | 1998-03-16 | Sigma Tau Ind Farmaceuti | 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare, |
| WO1999011271A1 (en) | 1997-08-29 | 1999-03-11 | Dalhousie University | Use of polycyclic steroid compounds for the manufacture of a medicament for the treatment of cystic kidney diseases, vascular infarction, uremia and related conditions |
| AU3467699A (en) * | 1998-04-14 | 1999-11-01 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
| GB0003524D0 (en) * | 2000-02-15 | 2000-04-05 | Btg Int Ltd | Cytoprotective steroids (II) |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
-
2001
- 2001-08-14 GB GB0119810A patent/GB2378898A/en not_active Withdrawn
-
2002
- 2002-08-13 AT AT02755176T patent/ATE429919T1/de active
- 2002-08-13 CN CN028202627A patent/CN1700920B/zh not_active Expired - Fee Related
- 2002-08-13 KR KR1020047002137A patent/KR100895281B1/ko not_active IP Right Cessation
- 2002-08-13 JP JP2003520750A patent/JP4541698B2/ja not_active Expired - Fee Related
- 2002-08-13 AU AU2002321472A patent/AU2002321472B2/en not_active Ceased
- 2002-08-13 EP EP02755176A patent/EP1416937B1/en not_active Expired - Lifetime
- 2002-08-13 ES ES02755176T patent/ES2324859T3/es not_active Expired - Lifetime
- 2002-08-13 IL IL16036202A patent/IL160362A0/xx active IP Right Grant
- 2002-08-13 RU RU2004104362/15A patent/RU2329049C2/ru not_active IP Right Cessation
- 2002-08-13 WO PCT/GB2002/003770 patent/WO2003015791A1/en active Application Filing
- 2002-08-13 DE DE60232154T patent/DE60232154D1/de not_active Expired - Lifetime
- 2002-08-13 CA CA2457050A patent/CA2457050C/en not_active Expired - Fee Related
- 2002-08-13 NZ NZ531100A patent/NZ531100A/en not_active IP Right Cessation
- 2002-08-13 DK DK02755176T patent/DK1416937T3/da active
- 2002-08-13 PT PT02755176T patent/PT1416937E/pt unknown
- 2002-08-13 US US10/486,499 patent/US8148355B2/en not_active Expired - Fee Related
-
2004
- 2004-02-12 IL IL160362A patent/IL160362A/en not_active IP Right Cessation
- 2004-03-12 NO NO20041057A patent/NO334819B1/no not_active IP Right Cessation
- 2004-10-29 HK HK04108498.6A patent/HK1065703A1/xx unknown
-
2009
- 2009-07-20 CY CY20091100767T patent/CY1109233T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60232154D1 (de) | 2009-06-10 |
| KR100895281B1 (ko) | 2009-04-29 |
| IL160362A0 (en) | 2004-07-25 |
| RU2329049C2 (ru) | 2008-07-20 |
| NO20041057L (no) | 2004-03-12 |
| CA2457050C (en) | 2010-10-12 |
| AU2002321472B2 (en) | 2007-11-08 |
| EP1416937A1 (en) | 2004-05-12 |
| RU2004104362A (ru) | 2005-05-10 |
| KR20040041577A (ko) | 2004-05-17 |
| CN1700920B (zh) | 2012-05-30 |
| CA2457050A1 (en) | 2003-02-27 |
| US8148355B2 (en) | 2012-04-03 |
| GB0119810D0 (en) | 2001-10-10 |
| JP2005506321A (ja) | 2005-03-03 |
| EP1416937B1 (en) | 2009-04-29 |
| CN1700920A (zh) | 2005-11-23 |
| NO334819B1 (no) | 2014-06-10 |
| ES2324859T3 (es) | 2009-08-18 |
| NZ531100A (en) | 2006-02-24 |
| JP4541698B2 (ja) | 2010-09-08 |
| DK1416937T3 (da) | 2009-08-24 |
| CY1109233T1 (el) | 2014-07-02 |
| GB2378898A (en) | 2003-02-26 |
| IL160362A (en) | 2011-10-31 |
| PT1416937E (pt) | 2009-07-24 |
| WO2003015791A1 (en) | 2003-02-27 |
| ATE429919T1 (de) | 2009-05-15 |
| US20040248868A1 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| HK1066482A1 (en) | Use os fucans in the treatment of adhesions, arthritis and psoriasis | |
| IL169338A0 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
| TW200602030A (en) | Use of loteprednol etabonate for the treatment of dry eye | |
| IL173123A0 (en) | System and method for the photodynamic treatment of burns, wounds, and related skin disorders | |
| EP1571968A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| ZA200707934B (en) | Thereapeutic formulations for the treatment of beta-amyloid related diseases | |
| DK0933995T3 (da) | Fremgangsmåde til behandling af endotelskader | |
| WO2005037323A3 (en) | Use of gro to treat or prevent inflammation | |
| CY1109233T1 (el) | Προφυλακτικη και θεραπευτικη χρηση υδροξυστεροειδων | |
| WO2004054432A3 (en) | Methods and devices for therapeutic treatment cardiac and other pathologies | |
| MXPA05001885A (es) | El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica. | |
| IL177169A (en) | Use of n-(2-aryl- propionyl)-sulfonamides for the preparation of medicaments for the treatment of spinal cord injury | |
| NO20013414D0 (no) | Ny anvendelse av melagatran | |
| HK1085373A1 (en) | Compound and use in the manufacture of a medicament for the treatment of benign prostatic hyperplasia and associated symptoms | |
| HK1078460A1 (en) | Use of l-carnitine, actyl l-carnitine and propionyl l-carnitine in the manufacture of a combined medicament for the treatment of oligoasthenoteratospermia | |
| HUP0202638A2 (hu) | Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására | |
| WO2007117272A3 (en) | Methods for treatment of hemorrhagic shock and related disorders | |
| WO2002076930A3 (en) | Substituted diarylureas as stimulators for fas-mediated apoptosis | |
| AU2003252178A1 (en) | Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals | |
| IL153541A0 (en) | The use of 7-hydroxyepiandrosterone for the manufacture of pharmaceutical compositions | |
| PL1818052T3 (pl) | Zastosowanie formoterolu w profilaktycznym i/lub terapeutycznym leczeniu wyniszczenia mięśniowego i/lub zespołu wyniszczenia, związanych ze stanami katabolicznymi w przebiegu niektórych chorób, takich jak nowotwory, AIDS, zakażenia, cukrzyca i inne | |
| WO2003045428A3 (de) | Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung | |
| MXPA05012696A (es) | Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica. | |
| AU2003219664A1 (en) | Methods and therapeutic compositions in the treatment of advanced cancer |